ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"This is a historical milestone for ImmunAbs." said Dr. DongJo Kim, the company's CEO. "We are delighted to see IM-101's efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments."
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
SEOUL, South Korea -- Businesswire -- ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is “Hope for Patients, Dreams for All.” Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:ImmunAbs
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 무료 관람 무용 축제, 앰비규어스댄스컴퍼니 ‘2024 페스티벌 99.9’ 6월 한강 세빛섬 야외무대서
- 삼성스토어, 전기차 충전소 매장 확대…고객 편의 강화 - 뉴스와이어
- LG화학, 국내 민간기업 최대 규모 풍력발전 재생에너지 확보 - 뉴스와이어
- 대한항공, 에어라인 레이팅스 ‘올해 최고 항공사 중 2위’ - 뉴스와이어
- 이찬원, 마이원픽 내 KM차트 5월 선호도 조사 참여도 전체 1위 달성 - 뉴스와이어
- 한화그룹 ‘타임 세계 영향력 있는 100대 기업’ 선정 - 뉴스와이어
- 상상이 현실이 되는 바다 ‘제14회 화성 뱃놀이 축제’ 개막 - 뉴스와이어
- ‘2024 박물관·미술관 주간’ 행사 성료 - 뉴스와이어
- 아모레퍼시픽, 중국·북미·일본 법인장 인사 - 뉴스와이어
- 닛폰 산소 홀딩스, 호주 자회사가 호주 북부·서부의 LPG 사업 인수 - 뉴스와이어